ASTELLAS PHARMA
- Country
- π―π΅Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESN364 in Healthy Japanese Male and Pre- and Post-menopausal Female Subjects
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 44
- Registration Number
- NCT03436849
- Locations
- π―π΅
Site JP00001, Fukuoka, Japan
A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder
- First Posted Date
- 2018-01-19
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 369
- Registration Number
- NCT03403790
- Locations
- π―π΅
Site JP00005, Akita, Japan
π―π΅Site JP00038, Ehime, Japan
π―π΅Site JP00007, Fukushima, Japan
ASP8302 Single and Multiple Ascending Oral Dose Study in Non-elderly Healthy Japanese Subjects
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 56
- Registration Number
- NCT03361540
- Locations
- π―π΅
Site JP00001, Toshima, Tokyo, Japan
Development of Visual Function Evaluation Method
- Conditions
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 18
- Registration Number
- NCT03281005
- Locations
- π―π΅
Site JP00001, Meguro-ku, Tokyo, Japan
A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 66
- Registration Number
- NCT03257852
- Locations
- π―π΅
Site JP00016, Ichinomiya, Japan
π―π΅Site JP00005, Kitamoto, Japan
π―π΅Site JP00011, Oita, Japan
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 219
- Registration Number
- NCT03219333
- Locations
- πΊπΈ
Johns Hopkins Medical Center, Baltimore, Maryland, United States
πΊπΈJames Cancer Hospital / Ohio State University, Columbus, Ohio, United States
πΊπΈUniversity of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Study to Evaluate the Safety and Tolerability of ASP8062 in Healthy Japanese Male and Female Subjects
- First Posted Date
- 2017-06-12
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 36
- Registration Number
- NCT03183739
- Locations
- π―π΅
Site JP00001, Sumida, Tokyo, Japan
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
- Conditions
- Interventions
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 276
- Registration Number
- NCT03182244
- Locations
- π¨π³
Site CN123, Huangpu Qu, China
π¨π³Site CN117, Jinan, China
π¨π³Site CN133, Lanzhou, China
A Dose-finding Study of ASP4070
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 150
- Registration Number
- NCT03101267
- Locations
- π―π΅
Site JP00001, Shinjuku, Tokyo, Japan
A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 19
- Registration Number
- NCT03070990
- Locations
- π―π΅
Site JP00005, Sendai, Miyagi, Japan
π―π΅Site JP00003, Tsukuba, Ibaraki, Japan
π―π΅Site JP00008, Suita, Osaka, Japan